Development, optimization and characterization of glycyrrhetinic acid-chitosan nanoparticles of atorvastatin for liver targeting.
Glycyrrhetinic acid-modified chitosan (mGA-suc-CTS) is used as liver-targeted carrier for drug delivery. In this study, nanoparticles were prepared by ionic gelation process, and glycyrrhetinic acid act as the targeting ligand. The structure of the product was confirmed by IR and NMR techniques. The main aim of this study was to deliver atorvastatin directly to the liver by using same conjugate and reduce the associated side-effects, i.e. hepatotoxicity at high dose. Characterization of the developed formulation was performed by differential scanning calorimetry, particle size measurements and cellular uptake studies. Release profile, pharmacokinetics studies and organ distribution studies showed that developed formulation shows a relative higher liver uptake. The optimized formulation showed increased plasma concentration than the CTS nanoparticles as well as plain drug and the accumulation in the liver was nearly 2.59 times more than that of obtained with the CTS nanoparticles. Pharmaceutical and pharmacological indicators suggested that the proposed strategy can be successfully utilized for liver targeting of therapeutics.
a Department of Pharmaceutics and.
Raman
R
Rohilla
a Department of Pharmaceutics and.
Tarun
T
Garg
b Department of Pharmaceutical Chemistry , ISF College of Pharmacy , Moga , Punjab , India.
Jitender
J
Bariwal
a Department of Pharmaceutics and.
Amit K
AK
Goyal
a Department of Pharmaceutics and.
Goutam
G
Rath
D000069059:Atorvastatin / Q000737:chemistry*; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical / Q000379:methods; D048271:Chitosan / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D006034:Glycyrrhetinic Acid / Q000737:chemistry*; D056945:Hep G2 Cells; D006801:Humans; D008099:Liver / Q000187:drug effects*; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size
D004337:Drug Carriers; D048271:Chitosan; D000069059:Atorvastatin; D006034:Glycyrrhetinic Acid
Atorvastatin; drug delivery; glycyrrhetinic acid-modified chitosan; liver targeting; nanoparticles